QN-01 is under clinical development by Qnovia and currently in Phase I for Smoking Cessation. According to GlobalData, Phase I drugs for Smoking Cessation does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the QN-01 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QN-01 overview
QN-01 is under development for the treatment of smoking cessation. It is administered through inhalational route and is being developed based on RespiRx delivery platform.
Qnovia overview
Qnovia, formerly Respira Technologies, is a pharmaceutical company that develops inhaled therapeutic solutions. The company has developed RespiRX, an inhaled drug delivery device that facilitates nicotine replacement therapy for smokers to quit smoking. It also offers a vibrating mesh nebulizer that features a digital metered dose interface and Bluetooth-connected mobile app functionality. Qnovia’s device platform works for the treatment of asthma, smoking cessation, chronic obstructive pulmonary disease (COPD), oncology, novel respiratory therapies, vaccine delivery, and others. The company works in collaboration with Jabil, Altasciences, Propharma Group and Amplifybio, among others. Qnovia is headquartered in Richmond, Virginia, the US.
For a complete picture of QN-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
